A total of 13 patients were evaluable for response to sorafenib and 23 patients were evaluable for response to S+C / T. Objective response rate ( RR ) was 15 % for patients on sorafenib vs. 61 % for patients on S+C / T ( p = 0.014 ) ; stable disease was seen in 62 % and 35 % , respectively .